1 | 9316879 | Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. | J Pharmacol Exp Ther | 1997 Sep |
1 |
2 | 10199816 | Effect of selective proteasome inhibitors on TNF-induced activation of primary and transformed endothelial cells. | Am J Physiol | 1999 Apr |
4 |
3 | 10363983 | Proteasome inhibitors: a novel class of potent and effective antitumor agents. | Cancer Res | 1999 Jun 1 |
1 |
4 | 10499643 | The proteasome inhibitor PS-341 in cancer therapy. | Clin Cancer Res | 1999 Sep |
1 |
5 | 11306489 | The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. | Cancer Res | 2001 Apr 1 |
6 |
6 | 11316563 | Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. | Int J Radiat Oncol Biol Phys | 2001 May 1 |
3 |
7 | 11350913 | Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. | Clin Cancer Res | 2001 May |
13 |
8 | 11400168 | 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. | J Cell Biochem | 2001 Apr 2-27 |
3 |
9 | 11468181 | TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. | Blood | 2001 Aug 1 |
5 |
10 | 11489836 | Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. | Clin Cancer Res | 2001 Aug |
2 |
11 | 11494147 | The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. | Oncogene | 2001 Jul 27 |
3 |
12 | 11516199 | Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. | J Surg Res | 2001 Sep |
2 |
13 | 11740818 | Novel therapies targeting the myeloma cell and its bone marrow microenvironment. | Semin Oncol | 2001 Dec |
11 |
14 | 11755313 | Ethanol withdrawal induced CYP2E1 degradation in vivo, blocked by proteasomal inhibitor PS-341. | Free Radic Biol Med | 2002 Jan 1 |
3 |
15 | 11772267 | Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias. | Expert Opin Investig Drugs | 2001 Aug |
2 |
16 | 11861386 | Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. | Cancer Res | 2002 Feb 15 |
2 |
17 | 12010810 | Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. | Blood | 2002 Jun 1 |
1 |
18 | 12170431 | Hematologic malignancies: new developments and future treatments. | Semin Oncol | 2002 Aug |
1 |
19 | 12226754 | The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. | Oncogene | 2002 Sep 19 |
4 |
20 | 12391322 | Molecular sequelae of proteasome inhibition in human multiple myeloma cells. | Proc Natl Acad Sci U S A | 2002 Oct 29 |
5 |
21 | 12393500 | Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. | Blood | 2003 Feb 15 |
9 |
22 | 12492117 | PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. | Mol Cancer Ther | 2002 Aug |
4 |
23 | 12516957 | Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. | Mol Cancer Ther | 2002 Dec |
1 |
24 | 12538487 | Function of nuclear factor kappaB in pancreatic cancer metastasis. | Clin Cancer Res | 2003 Jan |
4 |
25 | 12548578 | Moving disease biology from the lab to the clinic. | Cancer | 2003 Feb 1 |
1 |
26 | 12631619 | The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. | Clin Cancer Res | 2003 Mar |
3 |
27 | 12631620 | Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. | Clin Cancer Res | 2003 Mar |
3 |
28 | 12637321 | The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. | Blood | 2003 Jul 1 |
2 |
29 | 12738240 | Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. | Cancer Treat Rev | 2003 May |
1 |
30 | 12738241 | Clinical update: proteasome inhibitors in hematologic malignancies. | Cancer Treat Rev | 2003 May |
2 |
31 | 12738242 | Clinical update: proteasome inhibitors in solid tumors. | Cancer Treat Rev | 2003 May |
4 |
32 | 12816986 | Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. | J Immunol | 2003 Jul 1 |
1 |
33 | 12821677 | Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. | J Biol Chem | 2003 Sep 5 |
8 |
34 | 12893773 | The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. | Blood | 2003 Nov 15 |
8 |
35 | 12902978 | The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. | Oncogene | 2003 Aug 7 |
12 |
36 | 12935973 | The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. | Haematologica | 2003 Aug |
3 |
37 | 12943815 | Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. | J Surg Res | 2003 Jul |
8 |
38 | 14513055 | The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. | Leukemia | 2003 Oct |
13 |
39 | 14555528 | Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. | Clin Cancer Res | 2003 Oct 1 |
2 |
40 | 14555532 | Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. | Clin Cancer Res | 2003 Oct 1 |
2 |
41 | 14559800 | Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. | Cancer Res | 2003 Oct 1 |
3 |
42 | 14612532 | The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. | Cancer Res | 2003 Nov 1 |
10 |
43 | 14627979 | Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. | Oncogene | 2003 Nov 20 |
15 |
44 | 14688479 | Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells. | Cancer Biol Ther | 2003 Nov-Dec |
11 |
45 | 14965369 | Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. | Cancer Sci | 2004 Feb |
25 |
46 | 15004512 | 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27. | Apoptosis | 2004 Mar |
3 |
47 | 15010285 | Proteasome inhibition induces cytokeratin accumulation in vivo. | Exp Mol Pathol | 2004 Apr |
3 |
48 | 15016328 | Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. | Cancer Sci | 2004 Mar |
10 |
49 | 15026548 | The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. | Mol Cancer Ther | 2004 Mar |
6 |
50 | 15039284 | Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. | Blood | 2004 Jul 15 |
13 |